key: cord-0893766-46odq6dw authors: Doherty, Jayne; O Morain, Neil; Stack, Roisin; Girod, Parker; Tosetto, Miriam; Inzitiari, Rosanna; Sheridan, Juliette; Cullen, Garret; Mc Dermott, Edel; Buckley, Maire; Horgan, Gareth; Mulcahy, Hugh; Ryan, Elizabeth J; Daghfal, David; Doran, Peter; O Morain, Colm; Doherty, Glen A title: Reduced serological response to COVID-19 vaccines in patients with IBD is further diminished by TNF inhibitor therapy; Early results of the VARIATION study (VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON) date: 2022-02-18 journal: J Crohns Colitis DOI: 10.1093/ecco-jcc/jjac029 sha: cdfb34fd758db1569d4054c1b015606f4dbd9f48 doc_id: 893766 cord_uid: 46odq6dw BACKGROUND AND AIMS: Evidence suggests patients with inflammatory bowel disease (IBD) receiving TNF-antagonists have attenuated response to vaccination against COVID-19. We sought to determine the impact of IBD and various medications for treatment of IBD on antibody responses to vaccination against COVID-19. METHODS: Patients with IBD (n=270) and healthy controls (HC, n=116) were recruited prospectively and quantitative antibody responses assessed following COVID-19 vaccination. The impact of IBD and medications for treatment of IBD on vaccine response rates was investigated. RESULTS: 100% of HC seroconverted post-complete vaccination with two vaccine doses. 2% of patients with IBD failed to seroconvert. Median anti-spike protein (SP) immunoglobulin (Ig)G levels post-complete vaccination in our IBD cohort was significantly lower than HC (2,613 AU/mL versus 6,871 AU/mL, p=<0.001). A diagnosis of IBD was independently associated with lower anti-SP IgG levels (β coefficient -0.2, p = 0.001). Use of mRNA vaccines was independently associated with higher anti-SP IgG levels (β coefficient 0.25, p = < 0.001). Patients with IBD receiving TNF-inhibitors had significantly lower anti-SP IgG levels (2,445AU/mL) than IBD patients not receiving TNF-inhibitors (3868AU/mL)(p = < 0.001). Patients with IBD not receiving TNF-inhibitors still showed attenuated responses compared to HC (3868AU/mL versus 8747AU/mL p = 0.001). CONCLUSIONS: Patients with IBD have attenuated serological responses to SARS-CoV-2 vaccination. Use of anti-TNF therapy negatively impacts anti-SP IgG levels further. Patients who do not seroconvert post-vaccination are a particularly vulnerable cohort. Impaired responses to vaccination in our study highlight the importance of booster vaccination programmes for patients with IBD. A c c e p t e d M a n u s c r i p t Manuscript Doi: 10.1093/ecco-jcc/jjac029 5 A novel coronavirus referred to as SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) was identified in late 2019 as the causative agent of a respiratory syndrome named Coronavirus-19 disease (COVID- 19) and has subsequently resulted in a worldwide pandemic. Given the immense morbidity and mortality associated with COVID-19 infection, accelerated vaccine development programs and mass vaccination campaigns were conducted with the introduction of novel vaccines {1-4}. Induction of protective immunity against SARS-CoV-2 following vaccination is critical to mitigate against severe disease, morbidity and mortality. To date data is limited on the impact of vaccine class on response rates in patients with IBD {11-13} or how different IBD therapies impact vaccine response after complete vaccination which we aimed to address in this study. We conducted a prospective multi-centre study supported by the INITIative collaborative research network (www.initiativeibd.ie) to assess immune response to both mRNA and Vaccines currently available in Ireland during this study were two mRNA vaccines (mRNA-1273 (Moderna)) or BNT162b2 (PFIZER/BIONTECH)) or two viral-vector vaccines (ChAdOx1 (AstraZeneca) or Ad26.CoV2.S (Janssen) vaccine). The study was approved by the relevant hospital research ethics committees. Eligible participants were evaluated at ≥1 of the following time points: (i) before first vaccination, (ii) prior to second vaccination, (iii) post complete vaccination. Variables recorded for participants included basic demographics (age, gender, co-morbidities and BMI) for all subjects. Data relating to IBD history including age at diagnosis, disease duration, IBD subtype, current medication at the time of vaccination, Faecal calprotectin (FCP), C-reactive protein (CRP) and albumin levels at the time of vaccination were collected. A c c e p t e d M a n u s c r i p t Manuscript Doi: 10.1093/ecco-jcc/jjac029 7 Blood samples were collected using the serum clot activator-coated blood collection tubes (BD Diagnostics, Cat 367837). All samples were spun for 10 min at 2000 × g at room temperature. Serum was aliquoted and stored at -80°C until analysis. The primary endpoint was immune response to vaccine assessed by quantitative immunoassay to evaluate levels of IgG to SARS-CoV-2 spike protein following first vaccination dose and complete vaccination. Secondary endpoints included prevalence of COVID-19 infection in our IBD cohort compared to our HCs by assessing semi -quantitative IgM in combination with IgG nucleocapsid (NC) antibody test (IgGNC) and the impact on levels of binding quantitative IgG SP, the impact of vaccine class, medications for treatment of IBD and IBD activity (FCP, CRP and albumin) on immune response to vaccination. Laboratory analyses were conducted in a single laboratory (Core Laboratory in the Clinical Research Centre, University College Dublin, Ireland) using the SARS-CoV-2 IgG 75 chemiluminescent microparticle immunoassay (CMIA) (Abbott Laboratories, IL, USA) run on the Architect i2000SR platform (Abbott Diagnostics) and the Abbott Alinity ci platform (Abbott Diagnostics) and the Abbott SARS-CoV-2 IgM assay run on the Abbott Architect i2000SR platform. Three analyses were conducted: (i) Abbott Alinity semi -quantitative IgM (IgMSP) assay. A cut -off of 1.0 (index value) which indicates reactivity/positivity was applied. (ii) quantitative IgG spike protein receptor binding domain (IgGSP RBD) serology, a quantitative measurement of anti-SP IgG that can be helpful to evaluate an individual's humoral response to vaccines. 50 AU/mL and above in this test are Statistical analyses were undertaken using SPSS version 26 (IBM). Participants with missing data were excluded from analysis. All tests were two tailed, and p values <0.05 were considered significant. Continuous data were reported as median and IQR, and discrete data as numbers and percentages, unless otherwise stated. Univariate analyses, using Mann-Whitney U tests, Kruskal-Wallis non-parametric test or one-way analysis of variance (ANOVA) were used to identify demographic and treatment related factors including medication type and vaccine class associated with anti-SP IgG levels. A two-tailed Spearmans correlation co-efficient was used to assess for differences in median anti-SP IgG levels in our IBD patients with FCP, CRP and albumin levels. We used a multivariable logistic regression model to identify factors independently associated with seropositivity including BMI, age at vaccination, gender and IBD subtype. Standardized β coefficients were obtained from linear regression. A c c e p t e d M a n u s c r i p t The frequency of co-morbidities in each cohort was low with no significant difference seen between HCs and our IBD cohort (p =ns) and are summarised in Table 1 . 108 HCs and 147 IBD patients had serum samples for IgM, IgG nucleocapsid (NC) antibody and IgG SP antibody levels prior to vaccination to assess for prior exposure to SARS-CoV-2. We observed similar frequency of prior COVID-19 infection in the two groups; 6/147 (4.1%) patients were positive for IgM and/or IgG nucleocapsid (NC) antibody compared to 3/108 (3.8%) in our HCs. 71 HCs (61.7%) received an mRNA vaccine and 44 (38.3%) received a VV vaccine. In our IBD cohort 215 patients (86.3%) were administered an mRNA vaccine and 34 (13.7%) a VV vaccine. Breakdown of vaccines administered is summarised in Table 1 . Median time from first vaccine administration to serologic assessment in our IBD cohort was 3. (Table 3a and 3b) . To determine if reduced antibody response observed in patients with IBD was secondary to IBD itself or anti-TNF therapy, we compared median anti-SP IgG levels between HCs, patients with IBD on anti-TNF therapy and patients with IBD not receiving anti-TNF therapy. We excluded participants receiving VV vaccines from this analysis given the low antibody titre observed in all study participants who received this class of vaccine. In total we included 65 HCs, 120 patients with IBD 16 anti-SP IgG Ab level of > 4000 has been found to correlate to >95% probability of high NA titre {31}. The proportion of patients with a limited antibody reserve (anti-SP IgG < 4000) was significantly higher in patients on anti-TNF therapy, anti-IL 12/23 therapy and JAK inhibitors, indicating these patients are particularly vulnerable for re-infection. Our study is the first to report a diagnosis of IBD negatively impacts anti-SP IgG titres postvaccination against COVID-19. In agreement with previous work {11,12} we found immunosuppression with anti-TNF therapy negatively impacts antibody response. However, a diagnosis of IBD itself also negatively impacts anti-SP IgG levels with IBD patients not receiving anti-TNF therapy having significantly lower anti-SARS-CoV-2 spike antibody levels than HCs. Our data raises the question as to why patients with IBD mount a less robust response to vaccination? This is most likely multifactorial and may be impacted by immune-system dysfunction and/or dysbiosis. There is a body of evidence highlighting immune-system dysfunction in patients with IBD {32, 33}. Reassuringly from samples taken prior to vaccination in our study rates of COVID-19 infection between HCs and our IBD cohort were similar (3.8% versus 4.1%). Of our patients with IBD who contracted COVID-19 all had mild symptoms and none required hospital admission. Finally, we found HCs who were previously infected with SARS-CoV2 had significantly higher Ab levels compared either to previously infected patients with IBD or uninfected HCs. The attenuated antibody response observed in patients with IBD who were exposed to the virus and subsequently received 2 doses of vaccine reinforces the advice that there should be no delay in vaccinating patients with IBD with previous infection with COVID-19 once symptoms have resolved. Limitations of our study include difference in gender ratio between IBD and HC groups and the relatively young age of participants (however this does reflect typical IBD population). Endoscopic data at the time of recruitment for patients with IBD was limited, therefore determining whether disease activity impacts Ab response was not possible. Number of patients on individual medication types including JAK inhibitors, anti-IL 12/23 inhibitors and patients on combination therapy were limited. Numbers of participants with a second set of follow-up antibody levels were small and we had no HC samples to compare them to. Numbers of patients and HCs with COVID-19 infection were small on sub-analysis. In conclusion, our study highlights that although seroconversion rates in patients with IBD vaccinated against COVID-19 are high, a small cohort of patients remain vulnerable to infection. Values measured by ELISA are presented as a linear scale (y axis represented as y = y/100) of IgG SP antibody levels post vaccination against COVID-19. Differences in anti-SP IgG levels post two vaccines of an mRNA vaccine in IBD patients on anti-TNF therapy, not receiving anti-TNF therapy and healthy controls. Statistical analysis was carried out using independent-samples Mann Whitney U test between each group. A c c e p t e d M a n u s c r i p t In this graph anti-SP IgG antibody levels are represented on the Y axis with error bars representing the interquartile range and time points at serum analysis represented on the x axis. Time 0 represents anti-SP IgG levels prior to vaccination, Time 1 represents anti-SP IgG levels after first vaccine, Time 2 represents first set of anti-SP IgG levels after complete vaccination against COVID-19 at a median of 6 weeks post vaccination and Time 3 represents second anti-SP IgG levels post complete vaccination at a median time of 12 weeks post complete vaccination. Statistical analysis was carried out using related-samples Friedmans 2-way ANOVA by ranks test for trends in anti SP IgG levels over the four timepoint. A Mann Whitney U test was used to compare median anti-SP IgG levels between our anti-TNF and non-anti-TNF cohort at timepoint 3. Oxford-AstraZeneca COVID-19 vaccine efficacy Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: a systematic review and metaanalysis International Organization for the Study of Inflammatory Bowel Disease (IOIBD) SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting th Interview COVID-19 ECCO Taskforce Contributors to the CLARITY IBD study. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab Dotan I; REsponses to COVid-19 vaccinE IsRaeli IBD group Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study | Pfizer Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine Moderate COVID-19 -Merck.com Centres for Disease Control and Prevention Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. The Lancet Regional Health -Europe Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA Vaccines. Vaccines (Basel) Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response Analysis of the maturation process of dendritic cells deficient for TNF and lymphotoxin-alpha reveals an essential role for TNF Anti-Tnf treatment blocks the induction of T cell-dependent humoral responses Do JAK inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIK-SFR Registry A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model Robust neutralizing antibodies to SARS-CoV-2 infection persist for months Abbott Alinity i SARS-CoV-2 IgG II Quant Reagent Instructions for Use Crohn's disease Innate and adaptive immunity in inflammatory bowel disease Toll-like receptors and inflammatory bowel disease Patients with active inflammatory bowel disease lack immature peripheral blood plasmacytoid and myeloid dendritic cells Dysbiosis in inflammatory bowel disease Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach The microbiome in inflammatory bowel disease: current status and the future ahead A pyrosequencing study in twins shows the gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes Antibiotics-Driven Gut Microbiome Perturbation Alters Immunity to Vaccines in Humans Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNFα therapy in inflammatory bowel disease patients: a report from the epi-IIRN Waning Immunity after the BNT162b2 Vaccine in Israel Dynamics of antibody response BNT162b2 vaccine after six months: a longitudinal prospective study. The Lancet Regional Health -Europe Covid-19 vaccine-induced antibodies are attenuated and decay rapidly in infliximab treated patients British Society of Gastroenterology Inflammatory Bowel Disease section and the Inflammatory Bowel Disease Clinical Research Group. Third doses of SARS-CoV-2 vaccines in immunosuppressed patients with inflammatory bowel disease A c c e p t e d M a n u s c r i p t